Cargando…
A randomized, controlled study to assess the efficacy and safety of lotilaner (Credelio™) in controlling ticks in client-owned dogs in Europe
BACKGROUND: Oral administration of lotilaner flavoured chewable tablets (Credelio™, Elanco) to dogs has been shown to provide a rapid onset of killing activity of infesting ticks, with sustained efficacy for at least 35 days. A study was undertaken in Europe to confirm lotilaner’s safety and anti-ti...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5664821/ https://www.ncbi.nlm.nih.gov/pubmed/29089058 http://dx.doi.org/10.1186/s13071-017-2478-9 |
_version_ | 1783275068490514432 |
---|---|
author | Cavalleri, Daniela Murphy, Martin Seewald, Wolfgang Drake, Jason Nanchen, Steve |
author_facet | Cavalleri, Daniela Murphy, Martin Seewald, Wolfgang Drake, Jason Nanchen, Steve |
author_sort | Cavalleri, Daniela |
collection | PubMed |
description | BACKGROUND: Oral administration of lotilaner flavoured chewable tablets (Credelio™, Elanco) to dogs has been shown to provide a rapid onset of killing activity of infesting ticks, with sustained efficacy for at least 35 days. A study was undertaken in Europe to confirm lotilaner’s safety and anti-tick efficacy in client-owned dogs. METHODS: In this assessor-blinded study, dogs were enrolled at 19 clinics in Germany, Hungary and Portugal. Qualifying households with no more than three dogs were randomized in an approximate 2:1 ratio to a lotilaner or fipronil/(S)-methoprene (FSM) (Frontline® Combo Spot-on, Merial) treatment group. One household dog with at least three live attached ticks was the primary dog. Treatments were dispensed Days 0, 28 (± 2) and 56 (± 2) for owner administration to all household dogs. Tick counts were performed on primary dogs Days 7 (± 1), and ±2 days on Days 14, 21, 28, 42, 56, 70 and 84; supplementary dogs were assessed for safety ± 2 days on Days 28, 56 and 84. Efficacy was assessed by comparing mean Day 0 live attached tick counts with subsequent counts. RESULTS: The most frequently retrieved ticks were Ixodes ricinus, Dermacentor reticulatus and Rhipicephalus sanguineus (sensu lato), with Ixodes hexagonus also present. In the lotilaner group (n = 127) geometric mean tick count reductions were at least 98% from the first post-treatment visit (Day 7) through Day 56, when efficacy was 100%. For FSM (n = 68), efficacy remained at least 96% through Day 84, but at no point were all dogs free of live attached ticks. Mean counts in lotilaner-treated dogs were significantly lower than FSM-treated dogs on Days 7, 42, 70 and 84 (P < 0.05). Percent efficacy over all post-enrolment visits was 99.3 and 98.3% for lotilaner and FSM groups, respectively (t ((190)) = 2.23, P = 0.0268). Owners successfully administered all treatments, and both products were well-tolerated. CONCLUSION: Under European field conditions, lotilaner flavoured chewable tablets administered monthly, were > 98% effective in eliminating live ticks from the first post-treatment assessment (Day 7) through Day 56 and maintained 100% of dogs tick-free on Days 70 and 84. Lotilaner was safe, providing superior tick control to FSM administered according to the same schedule. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13071-017-2478-9) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5664821 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-56648212017-11-08 A randomized, controlled study to assess the efficacy and safety of lotilaner (Credelio™) in controlling ticks in client-owned dogs in Europe Cavalleri, Daniela Murphy, Martin Seewald, Wolfgang Drake, Jason Nanchen, Steve Parasit Vectors Research BACKGROUND: Oral administration of lotilaner flavoured chewable tablets (Credelio™, Elanco) to dogs has been shown to provide a rapid onset of killing activity of infesting ticks, with sustained efficacy for at least 35 days. A study was undertaken in Europe to confirm lotilaner’s safety and anti-tick efficacy in client-owned dogs. METHODS: In this assessor-blinded study, dogs were enrolled at 19 clinics in Germany, Hungary and Portugal. Qualifying households with no more than three dogs were randomized in an approximate 2:1 ratio to a lotilaner or fipronil/(S)-methoprene (FSM) (Frontline® Combo Spot-on, Merial) treatment group. One household dog with at least three live attached ticks was the primary dog. Treatments were dispensed Days 0, 28 (± 2) and 56 (± 2) for owner administration to all household dogs. Tick counts were performed on primary dogs Days 7 (± 1), and ±2 days on Days 14, 21, 28, 42, 56, 70 and 84; supplementary dogs were assessed for safety ± 2 days on Days 28, 56 and 84. Efficacy was assessed by comparing mean Day 0 live attached tick counts with subsequent counts. RESULTS: The most frequently retrieved ticks were Ixodes ricinus, Dermacentor reticulatus and Rhipicephalus sanguineus (sensu lato), with Ixodes hexagonus also present. In the lotilaner group (n = 127) geometric mean tick count reductions were at least 98% from the first post-treatment visit (Day 7) through Day 56, when efficacy was 100%. For FSM (n = 68), efficacy remained at least 96% through Day 84, but at no point were all dogs free of live attached ticks. Mean counts in lotilaner-treated dogs were significantly lower than FSM-treated dogs on Days 7, 42, 70 and 84 (P < 0.05). Percent efficacy over all post-enrolment visits was 99.3 and 98.3% for lotilaner and FSM groups, respectively (t ((190)) = 2.23, P = 0.0268). Owners successfully administered all treatments, and both products were well-tolerated. CONCLUSION: Under European field conditions, lotilaner flavoured chewable tablets administered monthly, were > 98% effective in eliminating live ticks from the first post-treatment assessment (Day 7) through Day 56 and maintained 100% of dogs tick-free on Days 70 and 84. Lotilaner was safe, providing superior tick control to FSM administered according to the same schedule. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13071-017-2478-9) contains supplementary material, which is available to authorized users. BioMed Central 2017-11-01 /pmc/articles/PMC5664821/ /pubmed/29089058 http://dx.doi.org/10.1186/s13071-017-2478-9 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Cavalleri, Daniela Murphy, Martin Seewald, Wolfgang Drake, Jason Nanchen, Steve A randomized, controlled study to assess the efficacy and safety of lotilaner (Credelio™) in controlling ticks in client-owned dogs in Europe |
title | A randomized, controlled study to assess the efficacy and safety of lotilaner (Credelio™) in controlling ticks in client-owned dogs in Europe |
title_full | A randomized, controlled study to assess the efficacy and safety of lotilaner (Credelio™) in controlling ticks in client-owned dogs in Europe |
title_fullStr | A randomized, controlled study to assess the efficacy and safety of lotilaner (Credelio™) in controlling ticks in client-owned dogs in Europe |
title_full_unstemmed | A randomized, controlled study to assess the efficacy and safety of lotilaner (Credelio™) in controlling ticks in client-owned dogs in Europe |
title_short | A randomized, controlled study to assess the efficacy and safety of lotilaner (Credelio™) in controlling ticks in client-owned dogs in Europe |
title_sort | randomized, controlled study to assess the efficacy and safety of lotilaner (credelio™) in controlling ticks in client-owned dogs in europe |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5664821/ https://www.ncbi.nlm.nih.gov/pubmed/29089058 http://dx.doi.org/10.1186/s13071-017-2478-9 |
work_keys_str_mv | AT cavalleridaniela arandomizedcontrolledstudytoassesstheefficacyandsafetyoflotilanercredelioincontrollingticksinclientowneddogsineurope AT murphymartin arandomizedcontrolledstudytoassesstheefficacyandsafetyoflotilanercredelioincontrollingticksinclientowneddogsineurope AT seewaldwolfgang arandomizedcontrolledstudytoassesstheefficacyandsafetyoflotilanercredelioincontrollingticksinclientowneddogsineurope AT drakejason arandomizedcontrolledstudytoassesstheefficacyandsafetyoflotilanercredelioincontrollingticksinclientowneddogsineurope AT nanchensteve arandomizedcontrolledstudytoassesstheefficacyandsafetyoflotilanercredelioincontrollingticksinclientowneddogsineurope AT cavalleridaniela randomizedcontrolledstudytoassesstheefficacyandsafetyoflotilanercredelioincontrollingticksinclientowneddogsineurope AT murphymartin randomizedcontrolledstudytoassesstheefficacyandsafetyoflotilanercredelioincontrollingticksinclientowneddogsineurope AT seewaldwolfgang randomizedcontrolledstudytoassesstheefficacyandsafetyoflotilanercredelioincontrollingticksinclientowneddogsineurope AT drakejason randomizedcontrolledstudytoassesstheefficacyandsafetyoflotilanercredelioincontrollingticksinclientowneddogsineurope AT nanchensteve randomizedcontrolledstudytoassesstheefficacyandsafetyoflotilanercredelioincontrollingticksinclientowneddogsineurope |